and metalloproteinase) proteins belong to a family of membrane spanning metalloproteinases that cleave ectodomains of several substrates, including epidermal growth factor receptor (EGFR) ligands. 8 We have shown that ADAM17-mediated EGFR transactivation via heparin-binding EGF-like growth factor shedding is required for extracellular signal-regulated kinase activation but not for intracellular Ca 2+ elevation or Rho kinase activation. [9] [10] [11] Also, ADAM17 expression is enhanced in neointima after angioplasty, and dominant-negative ADAM17 gene transfer prevents neointimal hyperplasia. 12 Others have shown that ADAM17 expression is enhanced in atherosclerosis 13 and in the left ventricle on AngII infusion 14 and that an ADAM17 polymorphism is associated with cardiovascular mortality. 15 However, whether vascular ADAM17 manipulation has therapeutic potential against hypertensive complications remains completely unknown. Therefore, using mice lacking VSMC ADAM17 or treated with a human crossreactive ADAM17 antibody as well as with in vitro fibrosis assessment, we have tested our hypothesis that vascular ADAM17 is indispensable for cardiovascular remodeling but not for hypertension induced by AngII, thus, highlighting a unique therapeutic target in hypertension.
Methods

Animal Studies and the Tissue Analysis
Animal procedures were performed in accordance with National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals and Temple University IACUC guidelines. Eight-to 10-week-old male ADAM17 flox/flox sm22αCre +/− mice 16 and control ADAM17 flox/flox sm22αCre −/− mice were infused with AngII (Bachem, 1 μg/kg/min) for 2 weeks via osmotic mini-pump. 17 Eight-to 10-weekold male C57Bl6 mice (Jackson) were infused with AngII (Bachem, 1 μg/kg/min) and treated with human cross-reactive ADAM17 inhibitory antibody A9B8 18 or control human IgG2 (Athens Research & Technology) which was solubilized in PBS, 10 mg/kg/d intraperitoneal injection, at day 1 and day 7. Blood pressure and heart rate were evaluated in the conscious state by telemetry (Data Sciences International equipped with ADInstrument 6 software) via carotid catheter (PA-C10 transmitter). Cardiac function was measured using VisualSonics Velvo 2100 (M-mode). Plasma B-type natriuretic peptide and blood urea nitrogen concentrations were determined by the EIA kits (RayBiotech Inc and Stanbio Laboratories, respectively). Extracted hearts, kidneys, and aortas were fixed and used for histological studies as described previously. 19 To evaluate vascular hypertrophy and perivascular fibrosis in hearts and kidneys, serial cross-sections (5-μm-thick) were stained in Sirius Red (EMS, Hatfield PA). Briefly, after deparaffinization and rehydration, sections were stained in equal parts Weigert's Iron Hematoxylin A and B (EMS, Hatfield PA) for 10 minutes at room temperature. Sections were then washed twice in distilled water for 3 minutes per wash. Sirius Red was added for 1 hour at room temperature. Slides were washed twice in 0.01 N HCl for 3 minutes per wash. Sections were then dehydrated and penetrated using ethanol and xylene, respectively. Thoracic aortas were stained with Masson's trichrome protocol to distinguish medial area from adventitia. Briefly, after deparaffinization and rehydration, sections were incubated with Bouin's fluid for 1 hour at 56°C. Sections were washed three times in distilled water for 3 minutes per wash and then incubated with Working HE solution for 7.5 minutes followed by washing in distilled water for 30 s. Sections were then incubated with Biebrich ScarletAcid Fuchsin solution for 1 hour at 56°C. After incubation with phosphotungstic-phosphomolybdic acid solution for 5 minutes, sections were stained with Aniline Blue stain solution for 5 minutes. Sections were washed in 1% acetic acid for 30 s and in distilled water for 30 s. Sections were then dehydrated and penetrated using ethanol and xylene, respectively. Images were visualized on an Olympus IX81 inverted microscope using an Olympus SC30 high-resolution camera and were acquired with Olympus cellSens Entry 1.11 software. Analysis was conducted using ImageJ 1.50f software (http://rsb.info. nih.gov/ij).
To calculate vascular hypertrophy in the heart and kidney, the value of medial area was divided by the true area of the vessel. True area was calculated by vessel outer perimeter 2 divided by 4π. The value generated was the area of the vessel in true circular form. To calculate perivascular fibrosis, the value of fibrosis area was subtracted from vessel area and divided by the true area of the vessel. In total, 6 to 8 randomly selected samples per group were used for analysis. Three representative vascular images were analyzed per sample. Medial hypertrophy of thoracic aorta was quantified by measurements of medial thickness in 4 randomly selected locations per slide. Three representative vascular images were analyzed per sample. Adventitia of the aorta was not quantified because the area was occasionally damaged or removed during the dissection.
For immunohistochemistry, serial cross-sections were deparaffinized and blocked in 5% goat serum and 1% BSA for 1 hour at room temperature, incubated with primary antibody in PBS containing 1% BSA and 0.1% Tween 20 for 18 hours at 4°C, followed by biotinylated secondary antibody for 90 minutes at room temperature. Slides were incubated with avidin-biotin peroxidase complex for 30 minutes at room temperature, and staining was visualized with the substrate diaminobenzidine (Vector) producing a brown color and counterstained with hematoxylin. An equal concentration of control IgG was used side-by-side with each antibody to ensure staining specificity. 19 Quantification of the antibody staining was performed as reported previously with subtraction of the IgG background staining. 19 All images were visualized on Olympus SC30 high-resolution camera and were acquired with Olympus cellSens Entry 1.11 software using the same exposure time. Images were loaded into the ImageJ program for analysis. A vascular region of interest was drawn around the coronary arteries with the freehand selection tool. Adventitia was excluded from the quantification because the adventitial areas were limited in the arteries, except those with AngII infusion alone. All images were set to the same hue, saturation, and brightness. The area and intensity (optical density) in the region of interest were then measured and analyzed. Data were obtained from 4 mice in each group, with 3 to 4 nonoverlapping high-power fields for each antibody.
To evaluate ADAM17 mRNA expression, thoracic aortas and hearts were homogenized using BioMasher (Takara), and total RNA was extracted using TRIzol reagent (Invitrogen). cDNA was synthesized with RevertAid First Strand cDNA Synthesis Kit (Thermo). Quantitative real-time polymerase chain reaction was performed with SYBR Green qPCR Master Mix (Fermentas) as described previously. 20 mRNA abundance was calculated by normalization to ribosome 18S. The primers used were ADAM17: forward GGC GCG GGA GGG AGA AGT TT, reverse CGC CGC CTC ATG TTC CCG TC, ribosome 18S: forward AGT TCC AGC ACA TTT TGC GAG, reverse TCA TCC TCC GTG AGT TCT CCA.
Cell Culture and Experiments
VSMCs were prepared from thoracic aortas of male Sprague-Dawley rats by the explant method as described previously. 21 VSMCs were subcultured in DMEM containing 10% fetal bovine serum, penicillin, and streptomycin. Cells from passage 3 to 10 at 80% to 90% confluence were made quiescent by incubation with serum-free medium for 2 to 3 days. To avoid any potential phenotypic alteration, VSMCs were renewed every 2 to 3 months, and VSMCs from frozen stock were never used. The results were confirmed in at least 2 distinct cell preparations.
Immunoblotting was performed as previously described. 21 Quiescent VSMCs grown on 6-well plates were stimulated with 100 nmol/L AngII (Sigma) for specified durations. The reaction was terminated by the replacement of medium with 100 μL of 1×SDS lysis buffer. Forty microliter of the cell lysates were subjected to SDS-PAGE gel electrophoresis and electrophoretically transferred to a nitrocellulose membrane. The membranes were then exposed to primary antibodies overnight at 4°C. After incubation with the by guest on January 28, 2018
http://hyper.ahajournals.org/ Downloaded from peroxidase-linked secondary antibody for 1 hour at room temperature, immunoreactive proteins were visualized using a chemiluminescence reaction kit.
To evaluate profibrotic response, serum-starved VSMCs were stimulated with 100 nmol/L AngII for 48 hours, and extracellular cellular collagen content was quantified by Sirius Red collagen quantification kit (Chondrex) according to the manufacturer's protocol. Recombinant adenoviral vector encoding rat ADAM17 siRNA was created, and specificity and efficiency has been reported. 11 VSMCs were infected with 100 m.o.i. adenovirus before the AngII stimulation as reported previously.
11 ADAM17-selective inhibitor compound no 21 (JG26) 8 was generated as reported. VSMCs were pretreated with 1 μmol/L JG26 or vehicle (0.1% DMSO in final) for 30 minutes before the AngII stimulation. 4-Phenylbutyrate was obtained from Scandinavian Formulas and solubilized in DMEM. VSMCs were pretreated with 10 mmol/L 4-phenylbutyrate for 30 minutes. Erlotinib (OSI Pharmaceuticals) was obtained from Genentech. VSMCs were pretreated with 1 μmol/L erlotinib for 30 minutes.
Antibodies
Antibodies against Tyr 1068 -phosphorylated EGFR for immunohistochemistry (2234) and Ser
51
-phosphorylated eIF2α were purchased from Cell Signaling. Antibody against Tyr 1068 -phosphorylated EGFR for immunoblotting (44788G) was purchased from Invitrogen. Antibody against KDEL for detection of an endoplasmic reticulum (ER) stress marker GRP78 (ADI-SPA-827) was purchased from Enzo Life Sciences. Antibodies against ADAM17 for immunoblotting (sc-13973), EGFR (sc-03), and an ER stress marker, CHOP-10/GADD-153 (sc-575), were purchased from Santa Cruz Biotechnology. Antibodies against ADAM17 for immunohistochemistry (ab39163) were purchased from Abcam. Antibodies against Cre recombinase (MAB3120) and GAPDH (MAB374) were purchased from Millipore.
Statistical Analysis
Data are presented as mean±SEM or SD where appropriate. Differences between the multiple groups were analyzed by 1-way or 2-way analysis of variance, followed by the Tukey's post hoc test. Statistical significance was set at P<0.05.
Results
Prevention of AngII-Induced Cardiovascular Remodeling in Mice Lacking VSMC ADAM17
VSMC ADAM17-deficient ADAM17 flox/flox sm22αCre +/− mice were generated, 16 and vascular selective Cre expression was confirmed ( Figure S1A in the online-only Data Supplement). VSMC ADAM17-deficient mice and littermate control ADAM17 flox/flox sm22αCre −/− mice were infused with 1 μg/kg/ min AngII for 2 weeks. In control littermate mice, 2 weeks of AngII infusion caused vascular hypertrophy in aorta and coronary arteries that was markedly prevented in VSMC ADAM17-deficient mice. Perivascular fibrosis induced by AngII infusion was also prevented in VSMC ADAM17-deficient mice ( Figure 1A ; Figure S1B ). In control mice, AngII infusion for 2 weeks induced cardiac hypertrophy assessed by heart weight to body weight ratio and echocardiogram ( Figure 1B ; Table S1A ). Serum B-type natriuretic peptide and blood urea nitrogen concentrations were also elevated in these mice ( Figure S1C ). These cardiac and renal alterations by AngII infusion were attenuated in VSMC ADAM17-deficient mice. In contrast, hypertension was induced in both groups infused with AngII at 2 weeks ( Figure 1C ; Table S1B ). AngII-induced vascular remodeling in control mice was associated with vascular-dominant EGFR activation and ER stress assessed by immunohistochemistry. These AngII responses were attenuated in VSMC ADAM17-deficient mice. ADAM17 expression was barely detectable in heart or kidney but was significantly induced on AngII infusion in the vasculature. No such induction was observed in VSMC ADAM17-deficient mice (Figure 2 ; Figure S2 ). Quantitative polymerase chain reaction analysis of aortic mRNA confirmed ADAM17 induction by AngII as well as vascular ADAM17 silencing. ADAM17 mRNA was also increased in whole heart with AngII infusion in control mice but not in VSMC ADAM17-deficient mice ( Figure S3 ). In addition, although statistically insignificant, cardiac ADAM17 mRNA expression tends to be less in saline-infused VSMC ADAM17-deficient mice compared with saline-infused control mice.
Human Cross-Reactive ADAM17 Antibody Attenuates Cardiovascular Remodeling Induced by AngII
To ascertain that ADAM17 represents a novel therapeutic target contributing to target organ remodeling, AngII-infused C57Bl6 mice were treated with a human cross-reactive ADAM17 inhibitory antibody A9B8.
18 C57Bl/6 mice were . A9B8 prevented AngII-induced cardiovascular hypertrophy and perivascular fibrosis but not hypertension or its development. These responses were associated with suppression of ER stress (Figure 3 ; Figure S4 and Table S2A and S2B).
ADAM17 Antibody, a Small Molecule ADAM17 Inhibitor or Adenovirus Encoding ADAM17 siRNA, Attenuates a Fibrotic Response Induced by AngII In Vitro
To test for the role of ADAM17 in AngII-induced vascular fibrosis, extracellular collagen content was evaluated in VSMCs stimulated with AngII. Adenovirus encoding ADAM17 siRNA 11 attenuated the AngII-induced enhancement in collagen content ( Figure 4A and 4B) . Treatment of VSMCs with ADAM17 antibody A9B8, a highly selective ADAM17 inhibitor JG26/compound 21, 22 an EGFR kinase inhibitor erlotinib or a chemical ER chaperone 4-phenylbutyrate also attenuated AngII-induced enhancement in collagen content ( Figure 4C ; Figure S5A-S5C ). As shown with the ADAM17 siRNA, 11 A9B8 as well as JG26 inhibited AngII-induced EGFR transactivation assessed with an auto-phosphorylation site antibody ( Figure 4D ; Figure S5D ).
Discussion
The major finding of the present study is that AngII-induced cardiovascular hypertrophy and perivascular fibrosis but not hypertension were attenuated in mice lacking VSMC ADAM17 expression, as well as in mice treated with an ADAM17 antibody. The suppression of AngII-induced EGFR activation and vascular hypertrophy in ADAM17-deficient mice is in line with our past in vitro observations that genetic ADAM17 inhibition or silencing prevents EGFR transactivation and subsequent hypertrophic responses in cultured VSMCs. 9, 11 It is intriguing that VSMC silencing of ADAM17 or pharmacological inhibition of ADAM17 further prevented vascular fibrosis induced by AngII in vivo and in vitro. Faint expression of ADAM17 under normal conditions and enhanced expression in areas of interstitial fibrosis in damaged kidneys in humans have been reported. 23 Additionally, cardiac-specific heparin-binding EGF transgenic mice develop cardiac fibrosis. 24 AngII-induced renal interstitial fibrosis is attenuated in proximal tubule EGFRdeficient mice. 25 In our 2-week AngII infusion model, interstitial fibrosis in the heart or kidney was too marginal to be evaluated. However, it is likely that the paracrine production of heparin-binding EGF and activation of EGFR via induction and activation of ADAM17 in VSMCs may be critical for development of perivascular fibrosis associated with hypertension. 17, 26 In the present study with AngII-infused mice treated with an ADAM17 inhibitory antibody, hypertension was induced within a few days, with blood pressure values comparable to those of the control mice. The values are also in agreement with reported values in C57Bl6 background mice with AngII infusion. 27 Although these data suggest that ADAM17 inhibition or silencing has no alteration on the development of hypertension in response to AngII, lack of continued blood pressure recording is a limitation of the present study. This study could also include an additionally important ADAM17 wild/wild sm22Cre +/− control mouse group because endogenous lox-like sites are known to cause Cre-dependent chromosomal rearrangement in a Cre-transgenic mouse in the absence of loxP sequences. 28 Although the protocol is different, control sm22αCre +/− mice develop hypertension, cardiac hypertrophy, and vascular fibrosis in response to AngII infusion. 29 We have confirmed vascular dominant expression of the Cre transgene and intact presser responses to AngII in VSMC ADAM17-deficient mice or ADAM17 antibodytreated mice. However, contribution of VSMC ADAM17 to AngII-induced cardiac hypertrophy may require additional confirmation. Although lesser than smooth muscle, the sm22α promoter driver could show transgene expression in cardiac myocytes. 30 There is a tendency of cardiac ADAM17 reduction in ADAM17 flox/flox sm22αCre +/− mice, which could be because of a combination of VSMC and cardiac myocyte silencing in the heart according to literature. 31 Although the present study suggests that vascular-dominant ADAM17 and EGFR activation may mediate cardiac hypertrophy induced by AngII, cardiac myocyte-targeted expression of dominant-negative EGFR inhibits cardiac hypertrophy induced by AngII.
32 Therefore, future experiments in cardiac myocyte-specific ADAM17-deficient mice should be conducted to test the role of cardiac myocyte ADAM17 in cardiac hypertrophy induced by AngII.
ER stress has been implicated in cardiovascular diseases, 33 whereas limited information is available for its role in hypertension. 34 Our recent study suggests a potential prevention of hypertensive organ damage but not hypertension by 4-phenylbutyrate, which seems to involve VSMC ADAM17 as well as EGFR. 17 Inhibition of the fibrotic response in VSMCs with ER stress inhibition further suggests the presence of ER stressresponsible downstream signal transduction leading to vascular fibrosis, which likely involves transcriptional upregulation of several distinct genes.
17,20
Perspectives
The vascular ADAM17/EGFR signal transduction axis seems to be essential for cardiovascular remodeling associated with ER stress but not for hypertension in mice with AngII infusion. The signal seems to include a feed-forward mechanism involving vascular ADAM17 induction, which enhances EGFR ligand production and subsequent EGFR activation and vascular remodeling. Although the intervention with ADAM17 antibody in mice seems promising, additional research in large animals and humans will be necessary to seek for an add-on treatment against hypertensive complications. What Is New?
• Analysis of blood pressure and vascular pathology in the heart, kidney, and aorta with vascular smooth muscle cell ADAM17 deletion or ADAM17 inhibition by an antibody established a role for this metalloproteinase in Angiotensin II-induced pathological vascular remodeling independent of hypertension in mice.
• The concept of the feed-forward induction of vascular ADAM17 to amplify the epidermal growth factor receptor pathway and subsequent endoplasmic reticulum stress.
What Is Relevant?
• Vascular-restricted ADAM17 signal transduction highlights the importance of vascular pathology for subsequent tissue dysfunction in hypertension.
• Results indicating prevention of vascular remodeling but not hypertension by human cross-reactive ADAM17 antibody provide a foundation to seek a potential add-on therapy to current pressure-lowering treatments for hypertension.
Summary
In vascular smooth muscle ADAM17-deficient mice or mice treated with ADAM17 inhibitory antibody, vascular hypertrophy and perivascular fibrosis but not hypertension were prevented. Angiotensin II infusion showed vascular ADAM17 induction, epidermal growth factor receptor activation, and ER stress, which were attenuated in these mice. Cultured vascular smooth muscle cells were used to confirm the involvement of the ADAM17/epidermal growth factor receptor signaling axis in the induction of vascular fibrosis. Mean±SD (n=6), *p<0.001 compared with saline infusion. BW: body weight; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate.
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